IRIS
STELLA, STEFANIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.795
EU - Europa 1.255
AS - Asia 1.139
SA - Sud America 319
AF - Africa 267
OC - Oceania 1
Totale 5.776
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.733
IT - Italia 622
SG - Singapore 490
CN - Cina 368
BR - Brasile 299
IE - Irlanda 219
CI - Costa d'Avorio 184
IN - India 103
UA - Ucraina 81
DE - Germania 80
SN - Senegal 58
CA - Canada 51
KR - Corea 44
RU - Federazione Russa 44
VN - Vietnam 42
FI - Finlandia 35
GB - Regno Unito 35
SE - Svezia 24
BE - Belgio 22
FR - Francia 16
CZ - Repubblica Ceca 14
PL - Polonia 12
TR - Turchia 12
ES - Italia 10
IQ - Iraq 10
JP - Giappone 10
AR - Argentina 9
HK - Hong Kong 9
NL - Olanda 9
UZ - Uzbekistan 9
BD - Bangladesh 8
CH - Svizzera 8
NG - Nigeria 8
ID - Indonesia 7
IL - Israele 7
MA - Marocco 6
GR - Grecia 5
MX - Messico 5
AT - Austria 4
EC - Ecuador 4
NO - Norvegia 4
TN - Tunisia 4
IR - Iran 3
KZ - Kazakistan 3
ZA - Sudafrica 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BG - Bulgaria 2
CO - Colombia 2
HU - Ungheria 2
KE - Kenya 2
LB - Libano 2
LT - Lituania 2
PE - Perù 2
PY - Paraguay 2
RS - Serbia 2
SA - Arabia Saudita 2
TT - Trinidad e Tobago 2
AM - Armenia 1
AU - Australia 1
DO - Repubblica Dominicana 1
EG - Egitto 1
GL - Groenlandia 1
HN - Honduras 1
IS - Islanda 1
JM - Giamaica 1
JO - Giordania 1
NA - Namibia 1
NP - Nepal 1
PK - Pakistan 1
PS - Palestinian Territory 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
VE - Venezuela 1
Totale 5.776
Salva come PNG Salva come JPEG
Città #
Santa Clara 513
Dallas 473
Chandler 326
Singapore 318
Chicago 229
Dublin 219
Abidjan 184
Catania 177
Ashburn 98
Jacksonville 96
Hefei 85
Boardman 84
Kochi 79
Beijing 77
Cambridge 60
Lawrence 59
Dakar 57
Andover 55
Civitanova Marche 54
Los Angeles 50
Seoul 43
Palermo 38
Grafing 35
Nanjing 34
Des Moines 30
Wilmington 29
The Dalles 27
Dong Ket 26
Columbus 25
Milan 25
New York 25
Toronto 25
Brussels 22
Turku 22
Munich 19
Rome 19
Council Bluffs 18
São Paulo 17
Bari 15
Brno 13
Messina 13
San Mateo 13
Santa Venerina 12
Hanoi 11
Jiaxing 11
Nanchang 11
Ottawa 11
Belo Horizonte 10
Falls Church 10
Rio de Janeiro 10
Seattle 10
Tokyo 10
Aci Catena 9
Bremen 9
Saint Petersburg 9
Abuja 8
Brooklyn 8
Curitiba 8
Lappeenranta 8
Montreal 8
Boston 7
Brasília 7
Hanover 7
Hebei 7
Hong Kong 7
Pune 7
Redmond 7
San Francisco 7
Jakarta 6
London 6
Scottsdale 6
Warsaw 6
Chennai 5
Fairfield 5
Florence 5
Frankfurt am Main 5
Giardini-Naxos 5
Helsinki 5
Manaus 5
Manchester 5
Mascalucia 5
San Giovanni la Punta 5
Shenyang 5
Tashkent 5
Verona 5
Atlanta 4
Belém 4
Casablanca 4
Changsha 4
Comiso 4
Cosenza 4
Edinburgh 4
Fantina 4
Grammichele 4
Hangzhou 4
Juiz de Fora 4
Modica 4
Redwood City 4
Ribeirão Preto 4
Siracusa 4
Totale 4.204
Salva come PNG Salva come JPEG
Nome #
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib 175
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 127
Activation of the IGF axis in thyroid cancer: Implications for tumorigenesis and treatment 123
The Q-LAMP Method Represents a Valid and Rapid Alternative for the Detection of the BCR-ABL1 Rearrangement in Philadelphia-Positive Leukemias 120
Mutational Analysis of BRCA1 and BRCA2 Genes in Breast Cancer Patients from Eastern Sicily 120
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 119
High BCR-ABL/GUSISlevels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib 118
Biomarkers and prognostic factors for malignant pleural mesothelioma 112
AKT Inhibitors: New Weapons in the Fight Against Breast Cancer? 108
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 108
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 105
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice 104
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report 102
B-ALL relapses after autologous stem cell transplantation associated with a shift from e1a2 to e14a2 BCR-ABL transcripts: A case report 101
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report 101
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives 101
A case of high-risk AML in a patient with advanced systemic mastocytosis 100
Effect of combined epigenetic treatments and ectopic NIS expression on undifferentiated thyroid cancer cells 100
Rufloxacin induced photosensitization in bio-models of increasing complexity 99
Double-face activity of resveratrol in voluntary runners: assessment of DNA damage by comet assay. 96
New insights in thyroid cancer and p53 family proteins 96
Efficacy of Nilotinib in a CML Patient Expressing the Three-way Complex Variant Translocation t(2;9;22) 96
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. 95
Suppression of survivin induced by BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs 93
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts 93
Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far 90
Next generation sequencing in a cohort of patients with rare sarcoma histotypes: A single institution experience 90
Mechanistic Translation of Melanoma Genetic Landscape in Enriched Pathways and Oncogenic Protein-Protein Interactions 89
An Optimized NGS Workflow Defines Genetically Based Prognostic Categories for Patients with Uveal Melanoma 89
Combined inhibition of bcl2 and bcr-abl1 exercises anti-leukemia activity but does not eradicate the primitive leukemic cells 86
Successful management of a pregnant patient with chronic myeloid leukemia receiving standard dose imatinib 85
Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report 85
Opportunities and challenges of liquid biopsy in thyroid cancer 84
Uncommon long-term survival in a patient with chronic myeloid leukemia 82
Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias 82
Associations of classic Kaposi sarcoma with common variants in genes that modulate host immunity 82
Detection and clinical implications of a novel BCR-ABL1 E12A2 insertion/deletion in a CML patient expressing the E13A2 isoform 81
Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma 80
Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors 77
Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in-CML study 77
Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase 76
IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation. 75
Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer 74
Approcci Terapeutici Innovativi per il Trattamento di Cellule di Leucemia Mieloide Cronica Resistenti ad Imatinib Mesilato 72
THE ROLE OF SPARC IN CHRONIC MYELOID LEUKEMIA 72
The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study 71
Correlates of Human Herpesvirus-8 DNA detection among adults in Italy without Kaposi sarcoma 71
High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability 70
Diagnosis of Chronic Myeloid Leukemia Early in Pregnancy 70
Rapid decline of philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3 BCR-ABL1 fusion transcript: A case report 70
Targeting BCL-2 as a therapeutic strategy for primary p210BCR-ABL1-positive B-ALL cells 70
Molecular pathogenesis and treatment perspectives for hypereosinophilia and hypereosinophilic syndromes 70
High BCR-ABL/GUS(IS) Levels at Diagnosis Are Associated with Unfavorable Responses to Standard Dose Imatinib 65
Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia 65
Effective targeting of breast cancer stem cells by combined inhibition of Sam68 and Rad51 65
Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia 64
The Role of New Technologies in Myeloproliferative Neoplasms 64
Second-line dasatinib therapy improved compliance and deep molecular responses in imatinib-intolerant chronic myeloid leukemia patients 62
Hyperdiploidy associated with a high BCR-ABL transcript level may identify patients at risk of progression in chronic myeloid leukemia 60
Glucose-dependent effect of insulin receptor isoforms on tamoxifen antitumor activity in estrogen receptor-positive breast cancer cells 59
In Silico Prediction of BRCA1 and BRCA2 Variants with Conflicting Clinical Interpretation in a Cohort of Breast Cancer Patients 58
The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy 58
Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis 55
PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance 55
Single-Cell Analysis in the Omics Era: Technologies and Applications in Cancer 54
REThinking the role of the RET oncogene in breast cancer 53
A Multiplex Assay for Fast PIK3CA Hotspot Mutation Characterization in a Single Specimen by 3-Color Digital PCR Analysis 53
The other side of the coin: dissecting molecular mechanisms behind hereditary breast cancer in search of therapeutic opportunities 52
Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain 50
Personalized strategies for CML patients considering discontinuation of tyrosine kinase inhibitors treatment 49
Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes 46
No Benefit from Hydroxyurea Pre-Treatment in Frontline Chronic Myeloid Leukemia Therapy and Evidence of Quantitative Changes in the BCR::ABL1 Transcript Level 36
Totale 5.955
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.836
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.836
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021255 0 0 0 14 68 20 27 2 53 3 33 35
2021/2022435 20 67 11 7 78 8 64 15 25 11 30 99
2022/20231.036 68 82 56 119 58 148 13 201 209 14 46 22
2023/2024553 44 83 26 24 19 132 8 33 7 23 112 42
2024/20252.107 30 330 79 152 412 291 166 64 75 143 255 110
2025/20261.186 253 240 584 109 0 0 0 0 0 0 0 0
Totale 5.955